Showing 1 - 7 results of 7 for search 'Ilan R Kirsch', query time: 0.03s Refine Results
  1. 1
    The “Comparative Growth Assay”: Examining the Interplay of Anti-cancer Agents with Cells Carrying Single Gene Alterations

    The “Comparative Growth Assay”: Examining the Interplay of Anti-cancer Agents with Cells Carrying Single Gene Alterations by Petr Hausner, David J. Venzont, Liam Grogan, Ilan R. Kirsch

    Published 1999-10-01
    Get full text
    Article
  2. 2
    Chromosomal Instability Is Associated with Higher Expression of Genes Implicated in Epithelial-Mesenchymal Transition, Cancer Invasiveness, and Metastasis and with Lower Expression of Genes Involved in Cell Cycle Checkpoints, DNA Repair, and Chromatin Maintenance

    Chromosomal Instability Is Associated with Higher Expression of Genes Implicated in Epithelial-Mesenchymal Transition, Cancer Invasiveness, and Metastasis and with Lower Expression... by Anna V. Roschke, Oleg K. Glebov, Samir Lababidi, Kristen S. Gehlhaus, John N. Weinstein, Ilan R. Kirsch

    Published 2008-11-01
    Get full text
    Article
  3. 3
    An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.

    An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency. by Julie M Bailis, Marcia L Gordon, Jesse L Gurgel, Alexis C Komor, Jacqueline K Barton, Ilan R Kirsch

    Published 2013-01-01
    Get full text
    Article
  4. 4
    Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia

    Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia by Carol Fries, Lik Wee Lee, Meenakshi Devidas, Yunfeng Dai, Karen R. Rabin, Sumit Gupta, Mignon L. Loh, Ilan R Kirsch, Brent Wood, Rachel E. Rau

    Published 2022-11-01
    Get full text
    Article
  5. 5
    Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

    Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients by Rodrigo Fonseca, Mariano Arribas, Julia E. Wiedmeier-Nutor, Yael N. Kusne, Miguel González Vélez, Heidi E. Kosiorek, Richard (Duke) J. Butterfield, Ilan R. Kirsch, Joseph R. Mikhael, A. Keith Stewart, Craig Reeder, Jeremy Larsen, P. Leif Bergsagel, Rafael Fonseca

    Published 2023-03-01
    Get full text
    Article
  6. 6
    Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

    Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients by Rodrigo Fonseca, Mariano Arribas, Julia E. Wiedmeier-Nutor, Yael N. Kusne, Miguel González Vélez, Heidi E. Kosiorek, Richard (Duke) J. Butterfield, Ilan R. Kirsch, Joseph R. Mikhael, A. Keith Stewart, Craig Reeder, Jeremy Larsen, P. Leif Bergsagel, Rafael Fonseca

    Published 2023-05-01
    Get full text
    Article
  7. 7
    Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

    Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myelo... by Travers Ching, Megan E. Duncan, Tera Newman-Eerkes, Mollie M. E. McWhorter, Jeffrey M. Tracy, Michelle S. Steen, Ryan P. Brown, Srivatsa Venkatasubbarao, Nicholas K. Akers, Marissa Vignali, Martin E. Moorhead, Drew Watson, Ryan O. Emerson, Tobias P. Mann, B. Melina Cimler, Pamela L. Swatkowski, Ilan R. Kirsch, Charles Sang, Harlan S. Robins, Bryan Howie, Anna Sherwood

    Published 2020-06-01
    Get full text
    Article

Search Tools: